Navigation Links
Echo Therapeutics Announces Second Quarter 2013 Financial Results
Date:8/8/2013

PHILADELPHIA, Aug. 8, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, today announced financial results for the quarter ended June 30, 2013.  Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.

Recent Corporate Highlights

  • Echo initiated a multi-center clinical trial of its Symphony CGM System in critically ill patients.  The Company expects to complete the study in the third quarter, and will subsequently submit the CE Mark Technical File for marketing approval in Europe.
  • A pre-submission package was provided to the U.S. Food and Drug Administration (FDA) for its Symphony CGM System for use in the hospital critical care environment.  Echo has scheduled a meeting with the FDA in the third quarter to obtain the FDA's guidance regarding the U.S. regulatory pathway for Symphony, the proper approach to refining the pivotal trial protocol and endpoints, and preparing the pre-marketing application.
  • Echo completed a public offering of approximately $11.3 million, after expenses, in June.
  • Echo received agreement on its clinical trial plan from its Notified Body in Europe and Institutional Review Board (IRB) approval from each of its four US clinical study sites for the clinical study supporting CE Marking for its Symphony CGM System.
  • Echo demonstrated the features and functionality of the Symphony CGM System in the critical care setting during a live webcast following the annual stockholders meeting in May.  Management plans additional demonstrations and exhibitions of Symphony at upcoming medical conventions.
  • "The second quarter was marked by continued progress in the development and clinical evaluation of our Symphony CGM System. We believe that we are well-positioned to secure CE Marking and to initiate the FDA pivotal trial," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "Our non-invasive continuous glucose monitor addresses the unique needs of critical care patients.  We are very excited about the prospects of helping patients and the healthcare practitioners who treat them, while building value for our shareholders."

    Second Quarter 2013 Financial ResultsEcho's net loss for the second quarter of 2013 was $3.3 million, or ($0.51) per share, compared to $3.2 million, or ($0.81) per share, for the second quarter of 2012.  Operating loss for the second quarter of 2013 was $6.1 million compared to $3.5 million for the second quarter of 2012.  Research and development expenses were $4.0 million for the second quarter of 2013 compared to $2.2 million in the prior year.  The increase in research and development expenses is primarily related to increased engineering and design expenses incurred with outside contractors and personnel.  General and administration expenses were $2.1 million for the second quarter of 2013 versus $1.3 million in the prior year.  The increase in general and administrative expenses was primarily due to increased Marketing and Manufacturing personnel, as well as expenses related to prelaunch marketing and manufacturing activities.  Echo reported a cash balance of approximately $11.6 million as of June 30, 2013.Conference Call
Management will host a conference call today starting at 9:00 AM ET.  To listen in and/or participate in the call, please dial (877) 300-8521.  The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at www.echotx.com.

    About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting.  Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104Connect With Us:
    - Visit our website at www.echotx.com 
    - Follow us on Twitter at www.twitter.com/echotx 
    - Join us on Facebook at www.facebook.com/echotx

     Echo Therapeutics, IncCondensed Consolidated Balance Sheets(Unaudited)   June 30,2013December 31,2012ASSETSCurrent Assets:Cash and cash equivalents

    $
    ,608,289$
    3,747,210Cash restricted pursuant to letters of credit

    657,463407,463Deferred financing costs, current portion

    968,004968,004Prepaid expenses and other current assets

    210,32175,626Total current assets

    13,444,0775,198,303Net property and equipment (including assets under capitalized leases)

    1,659,8521,638,395Intangible assets, net of accumulated amortization

    9,625,0009,625,000Deferred financing costs, net of current portion

    3,065,3263,549,328Other assets

    11,06610,566Total assets

    $
    27,805,321$
    20,021,592LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    $
    2,264,576$
    2,319,219Deferred revenue from licensing arrangements, current portion

    90,22890,228Capital lease obligations, current portion

    2,6562,527Derivative warrant liability

    909,1555,585,141Accrued expenses and other liabilities

    1,769,5291,581,448Total current liabilities

    5,036,1449,578,563Deferred revenue, note payable and capital lease obligation, net of current portion

    45,114212,423Total liabilities

    5,081,2589,790,986CommitmentsStockholders' Equity:Convertible preferred stock, Series C & D

    30,16030,160Common stock

    106,80144,374Additional paid-in capital

    126,818,839104,058,087Accumulated deficit

    (104,231,737)(93,902,015)Total stockholders' equity

    22,724,06310,230,606Total liabilities and stockholders' equity

    $
    27,805,321$
    20,021,592 

     

    Condensed Consolidated Statements of Operations(Unaudited) Three Months EndedJune 30,Six Months EndedJune 30,2013201220132012Licensing revenue

    $
    22,557$
    30,927$
    45,114$
    ,854Total revenues

    22,55730,92745,11461,854Operating Expenses:Research and development

    4,019,1492,200,3077,238,8723,591,952Selling, general and administrative

    2,098,3471,334,8524,397,7943,194,256Total operating expenses

    6,117,4963,535,15911,636,6666,786,208Loss from operations

    (6,094,939)(3,504,232)(11,591,552)(6,724,354)Other Income (expense):Interest income (expense), net

    (241,458)1,422(3,414,156)4,231Loss on disposals of assets

    -(21,272)-(21,272)Gain on revaluation of derivative warrant liability

    2,995,000369,7384,675,986601,281Other income (expense), net

    2,753,542349,8881,261,830584,240Net loss

    $
    (3,341,397)$
    (3,154,344)$   (10,329,722)$
    (6,140,114)Net loss per common share, basic and diluted

    $
    (0.51)$
    (0.81)$
    (1.73)$
    (1.58)Basic and diluted weighted average common shares outstanding

    6,594,5303,916,0645,987,3763,895,181 

    (Reflects 1-for-10 reverse stock split effective June 7, 2013)


    '/>"/>
    SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
    2. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
    3. Echo Therapeutics Schedules Second Quarter 2013 Financial Results for Thursday, August 8, 2013
    4. Prime Therapeutics adds 80 new jobs in Albuquerque
    5. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
    6. PTC Therapeutics To Host Second Quarter 2013 Financial Results Conference Call And Webcast
    7. Cell Therapeutics Reports Second Quarter 2013 Financial Results
    8. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
    9. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
    10. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
    11. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
    (Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
    (Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
    Breaking Medicine Technology:
    (Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
    (Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
    (Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
    (Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
    (Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
    Breaking Medicine News(10 mins):